Consolidated balance sheet as at December 31
in CHF 1 000 | Notes | 2023 | 2022 | |||
Current assets | ||||||
Cash and cash equivalents | 501 | 1 948 | ||||
Receivables from brokers | 1 829 | – | ||||
Securities | 2 634 714 | 3 051 349 | ||||
Other assets | 110 | 92 | ||||
2 637 154 | 3 053 389 | |||||
Total assets | 2 637 154 | 3 053 389 | ||||
Current liabilities | ||||||
Short-term borrowings from banks | 304 900 | 363 000 | ||||
Payables to brokers | 5 436 | – | ||||
Other short-term liabilities | 3 491 | 4 143 | ||||
Tax liabilities | 110 | 111 | ||||
313 937 | 367 254 | |||||
Total liabilities | 313 937 | 367 254 | ||||
Shareholders' equity | ||||||
Share capital | 11 080 | 11 080 | ||||
Treasury shares | (36 508) | (36 508) | ||||
Retained earnings | 2 348 645 | 2 711 563 | ||||
2 323 217 | 2 686 135 | |||||
Total liabilities and shareholders' equity | 2 637 154 | 3 053 389 | ||||
Net asset value per share in CHF | 42.35 | 49.00 |
The notes are an integral part of the consolidated financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 13, 2024.